We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CPRX posted Q2 adjusted EPS of $0.68 and revenues of $146.6M, topping consensus on both metrics.
Firdapse revenues rose 10% Y/Y to $84.8M, supported by growing demand and new LEMS diagnoses.
CPRX reaffirmed 2025 revenue guidance of $545M-$565M, driven by Firdapse and Agamree growth.
Catalyst Pharmaceuticals (CPRX - Free Report) reported adjusted earnings of 68 cents per share for the second quarter of 2025, beating the Zacks Consensus Estimate of 58 cents. The company had recorded adjusted earnings of 56 cents in the year-ago quarter.
Total revenues, the majority of which comprised product revenues, amounted to $146.6 million in the reported quarter, representing growth of 19% year over year. The recorded figure also surpassed the Zacks Consensus Estimate of $139 million.
Catalyst Pharmaceuticals’ top line primarily comprised revenues from the sale of Firdapse, the first approved drug for the treatment of Lambert-Eaton myasthenic syndrome (LEMS), and the epilepsy drug Fycompa (perampanel) CIII. Revenues generated from the sale of the newly launched muscle disease drug, Agamree (vamorolone), also contributed to the top line.
CPRX’s Q1 Results in Detail
Firdapse generated sales worth $84.8 million in the reported quarter, up 10% year over year, driven by organic sales growth. The reported figure, however, missed the Zacks Consensus Estimate of $88 million as well as our estimate of $87 million. The drug has been witnessing strong demand, increasing prescription rates from LEMS patients and continued diagnosis of new LEMS patients.
In 2023, Catalyst Pharmaceuticals acquired the U.S. rights for Fycompa (perampanel) CIII from Eisai Co., Ltd. This acquisition diversified the company’s portfolio by adding a commercial-stage epilepsy asset. Catalyst Pharmaceuticals started recording sales of Fycompa in 2023.
Fycompa generated net product revenues of $34.3 million, down 6% year over year, as tablet generics began hitting the market in late May following the expiry of the expiration of one of its patents. Oral suspension remains exclusive until mid-December 2025, but revenues are expected to decline with growing generic competition. The reported figure, however, surpassed the Zacks Consensus Estimate of $25.9 million as well as our model estimate of $26.7 million.
Year to date, shares of CPRX have gained 4.4% compared with the industry’s 5.9% growth.
Image Source: Zacks Investment Research
In 2023, Catalyst Pharmaceuticals acquired exclusive rights to manufacture and supply Agamree from Santhera Pharmaceuticals through a licensing agreement. In late 2023, the FDA approved Agamree for treating Duchenne Muscular Dystrophy (DMD) in patients aged two years and older, which gave the company a third approved product. The drug was commercially launched in the United States in the middle of March 2024.
In the reported quarter, Agamree generated revenues worth $27.4 million, up significantly year over year. The reported figure beat the Zacks Consensus Estimate of $25.1 million and our estimate of $25.2 million.
Research and development (R&D) expenses were $4.4 million in the reported quarter, up 46% year over year. Selling, general and administrative (SG&A) expenses totaled $45.9 million, up 13% year over year.
As of June 30, 2025, Catalyst Pharmaceuticals had cash, cash equivalents and investments worth $652.8 million compared with $580.7 million as of March 31, 2025.
CPRX Reaffirms 2025 Financial Guidance
In 2025, Catalyst Pharmaceuticals continues to expect total revenues between $545 million and $565 million, reflecting continued growth in product revenues from Firdapse and Agamree.
Firdapse revenues are expected between $355 million and $360 million. Agamree revenues are anticipated to be between $100 million and $110 million in the current year. Fycompa revenues are projected between $90 million and $95 million, which reflects the anticipated impact of the loss of market exclusivity of the drug in 2025.
Catalyst Pharmaceuticals expects its R&D expenses to be between $15 million and $20 million in 2025 due to investments in the SUMMIT study evaluating the long-term efficacy and safety of Agamree over other DMD treatments. SG&A expenses are expected to rise steadily in 2025.
Catalyst Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
In the past 60 days, estimates for CorMedix’s earnings per share have increased from 93 cents to 97 cents for 2025. During the same time, earnings per share estimates for 2026 have increased from $1.64 to $1.65. Year to date, shares of CRMD have rallied 47.5%.
CorMedix’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 25.82%.
In the past 60 days, estimates for Immunocore’s 2025 loss per share have narrowed from 86 cents to 68 cents. Loss per share estimates for 2026 have narrowed from $1.34 to $1.10 during the same period. IMCR stock has increased 8.8% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 76.18%.
In the past 60 days, estimates for Arvinas’ 2025 loss per share have narrowed from $1.51 to $1.50. Loss per share estimates for 2026 have narrowed from $3.08 to $2.98 during the same period. ARVN stock has plunged 66.5% year to date.
Arvinas’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 82.09%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y
Key Takeaways
Catalyst Pharmaceuticals (CPRX - Free Report) reported adjusted earnings of 68 cents per share for the second quarter of 2025, beating the Zacks Consensus Estimate of 58 cents. The company had recorded adjusted earnings of 56 cents in the year-ago quarter.
Total revenues, the majority of which comprised product revenues, amounted to $146.6 million in the reported quarter, representing growth of 19% year over year. The recorded figure also surpassed the Zacks Consensus Estimate of $139 million.
Catalyst Pharmaceuticals’ top line primarily comprised revenues from the sale of Firdapse, the first approved drug for the treatment of Lambert-Eaton myasthenic syndrome (LEMS), and the epilepsy drug Fycompa (perampanel) CIII. Revenues generated from the sale of the newly launched muscle disease drug, Agamree (vamorolone), also contributed to the top line.
CPRX’s Q1 Results in Detail
Firdapse generated sales worth $84.8 million in the reported quarter, up 10% year over year, driven by organic sales growth. The reported figure, however, missed the Zacks Consensus Estimate of $88 million as well as our estimate of $87 million. The drug has been witnessing strong demand, increasing prescription rates from LEMS patients and continued diagnosis of new LEMS patients.
In 2023, Catalyst Pharmaceuticals acquired the U.S. rights for Fycompa (perampanel) CIII from Eisai Co., Ltd. This acquisition diversified the company’s portfolio by adding a commercial-stage epilepsy asset. Catalyst Pharmaceuticals started recording sales of Fycompa in 2023.
Fycompa generated net product revenues of $34.3 million, down 6% year over year, as tablet generics began hitting the market in late May following the expiry of the expiration of one of its patents. Oral suspension remains exclusive until mid-December 2025, but revenues are expected to decline with growing generic competition. The reported figure, however, surpassed the Zacks Consensus Estimate of $25.9 million as well as our model estimate of $26.7 million.
Year to date, shares of CPRX have gained 4.4% compared with the industry’s 5.9% growth.
Image Source: Zacks Investment Research
In 2023, Catalyst Pharmaceuticals acquired exclusive rights to manufacture and supply Agamree from Santhera Pharmaceuticals through a licensing agreement. In late 2023, the FDA approved Agamree for treating Duchenne Muscular Dystrophy (DMD) in patients aged two years and older, which gave the company a third approved product. The drug was commercially launched in the United States in the middle of March 2024.
In the reported quarter, Agamree generated revenues worth $27.4 million, up significantly year over year. The reported figure beat the Zacks Consensus Estimate of $25.1 million and our estimate of $25.2 million.
Research and development (R&D) expenses were $4.4 million in the reported quarter, up 46% year over year. Selling, general and administrative (SG&A) expenses totaled $45.9 million, up 13% year over year.
As of June 30, 2025, Catalyst Pharmaceuticals had cash, cash equivalents and investments worth $652.8 million compared with $580.7 million as of March 31, 2025.
CPRX Reaffirms 2025 Financial Guidance
In 2025, Catalyst Pharmaceuticals continues to expect total revenues between $545 million and $565 million, reflecting continued growth in product revenues from Firdapse and Agamree.
Firdapse revenues are expected between $355 million and $360 million. Agamree revenues are anticipated to be between $100 million and $110 million in the current year. Fycompa revenues are projected between $90 million and $95 million, which reflects the anticipated impact of the loss of market exclusivity of the drug in 2025.
Catalyst Pharmaceuticals expects its R&D expenses to be between $15 million and $20 million in 2025 due to investments in the SUMMIT study evaluating the long-term efficacy and safety of Agamree over other DMD treatments. SG&A expenses are expected to rise steadily in 2025.
Catalyst Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Catalyst Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Catalyst Pharmaceuticals, Inc. Quote
CPRX’s Zacks Rank & Other Stocks to Consider
Catalyst Pharmaceuticals currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the biotech sector are Arvinas (ARVN - Free Report) , CorMedix (CRMD - Free Report) and Immunocore (IMCR - Free Report) . While CRMD and IMCR sport a Zacks Rank #1 (Strong Buy) each at present, ARVN currently carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for CorMedix’s earnings per share have increased from 93 cents to 97 cents for 2025. During the same time, earnings per share estimates for 2026 have increased from $1.64 to $1.65. Year to date, shares of CRMD have rallied 47.5%.
CorMedix’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 25.82%.
In the past 60 days, estimates for Immunocore’s 2025 loss per share have narrowed from 86 cents to 68 cents. Loss per share estimates for 2026 have narrowed from $1.34 to $1.10 during the same period. IMCR stock has increased 8.8% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 76.18%.
In the past 60 days, estimates for Arvinas’ 2025 loss per share have narrowed from $1.51 to $1.50. Loss per share estimates for 2026 have narrowed from $3.08 to $2.98 during the same period. ARVN stock has plunged 66.5% year to date.
Arvinas’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 82.09%.